Azitra (AZTR) Receivables (2022 - 2026)

Azitra's (AZTR) quarterly Receivables came in at $5108.0 in Q1 2026, up 460.09% on a QoQ basis from $912.0 in Q4 2025.

Azitra (AZTR) Receivables (2022 - 2026) Analysis & Trends

Azitra (AZTR) has 5 years of Receivables data on file, last reported at $5108.0 in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $5108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5108.0 (changed N/A YoY) and the FY2025 annual result came in at $912.0, up 291.42% from the prior year.
Receivables improved to $5108.0 in Q1 2026, from $912.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $885120.0 in Q2 2023 to a low of $233.0 in Q4 2024.
A 5-year average of $167826.2 and a median of $3482.5 in 2024 frame the typical range for Receivables.
Annual changes were most pronounced in 2024 — Receivables plunged 99.87% — and 2025, when it soared 291.42%.
Tracing AZTR's Receivables over 5 years: stood at $350000.0 in 2022, then slumped by 71.93% to $98255.0 in 2023, then tumbled by 99.76% to $233.0 in 2024, then soared by 291.42% to $912.0 in 2025, then surged by 460.09% to $5108.0 in 2026.
The last three Receivables figures came in at $5108.0 (Q1 2026), $912.0 (Q4 2025), and $233.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Azitra	2.44 Mn	2.44 Mn	-	909.00

Download Data